Brief: Kane Biotech Inc Announces Two Key Milestones As Dispersinb Wound Care Project Advances Towards Human Clinical Trials
13/07/2021 13:31
July 13 (Reuters) - Kane Biotech Inc KNE.V :
* KANE BIOTECH INC - ANNOUNCES TWO KEY MILESTONES AS
DISPERSINB
WOUND CARE PROJECT ADVANCES TOWARDS HUMAN CLINICAL TRIALS
* KANE BIOTECH INC - NEW MANUFACTURING PARTNERSHIP WITH DOW
DEVELOPMENT LABORATORIES, LLC FOR CLINICAL PRODUCT MANUFACTURING
* KANE BIOTECH INC - DEVELOPMENT OF A NOVEL TOPICAL HYDROGEL
FORMULATION OF DISPERSINB WITH SIGNIFICANTLY IMPROVED STABILITY
Source text for Eikon: ID:nGNXSL1xW
Further company coverage: KNE.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kane Biotech
See all newsBrief: Kane Biotech Announces FDA 510(K) Clearance For Revyve® Antimicrobial Skin And Wound Cleanser
Brief: Kane Biotech Restarts Commercial Activities And Strengthens North American Management
Brief: Kane Biotech Completes U.S. FDA 510(K) Submission For Revyve Antimicrobial Wound Cleanser
Brief: Kane Biotech Announces Second Quarter 2025 Financial Results
Brief: Kane Biotech provides further corporate update